Eli Lilly (LLY) has recently experienced a significant stock pullback, dropping 8.44% over the past month, from $1,218.49 to $1,115.70, while the S&P 500 only fell 1.06% in the same period. This decline was attributed to a 9% decrease in realized U.S. prices for its drugs, excluding rebate adjustments, and $2.78 billion in acquired IPR&D charges from various business development deals. Despite these factors, the company reported strong Q2 revenue of $22.97 billion, a 48% year-over-year increase, and raised its full-year 2026 revenue guidance to $85 billion to $87 billion.
Analyst sentiment remains largely positive, with a consensus Buy rating and a median 12-month price target of $1,392.50, implying a potential upside of about 22.38%. Berenberg upgraded Eli Lilly's rating from Hold to Buy on September 15, increasing its price target from $1,220 to $1,400, and sees potential for about 25% upside. Citi analyst Geoff Meacham raised his target from $1,500 to $1,600, suggesting over 40% upside, highlighting the company's leading position in the GLP-1 obesity and diabetes market with Mounjaro and Zepbound. Foundayo, Lilly's oral GLP-1 drug, is also showing rapid uptake, capturing over 30% of new U.S. patients starting oral weight-loss medications, with a global rollout anticipated for 2027.
The bull thesis for Eli Lilly is supported by the continued dominance of Mounjaro and Zepbound in the U.S. obesity prescription market, accounting for roughly 6 out of 10 total and 7 out of 10 injectable prescriptions. The anticipated diabetes approval for Foundayo and the upcoming BLA submission for retatrutide, a triple-agonist, in Q1 2027, are expected to drive further growth. Eli Lilly has invested approximately $60 billion in over 25 business development deals this year, with many new pipeline assets having multibillion-dollar sales potential, which analysts believe is underestimated. Catalysts include label expansion for tirzepatide into cardiovascular risk, retatrutide's filing, and Foundayo's international launch.
However, potential risks include a slower-than-expected expansion of the GLP-1 market, increased competition, greater-than-expected price erosion, or clinical setbacks. Q2 2026 results already showed a 3% decline in U.S. realized prices year-over-year, primarily due to Zepbound and Mounjaro. Despite these concerns, the company's strong operating results and upward revisions in Wall Street's earnings estimates suggest a positive outlook. Eli Lilly currently trades at $1,114.90 with a market cap near $995 billion and a forward P/E of 24. It has lagged the S&P 500 year-to-date, up 4.32% compared to the index's 12.08%.
